Activated prothrombin complex concentrate (FEIBA®) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience

Haemophilia, Supplement

Volumn 10, Issue 2, 2004, Pages 41-45

  Tjønnfjord, Geir E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Activated prothrombin complex concentrates; Haemophilia; Inhibitors; Myocardial infarction; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 ANTIBODY; DIURETIC AGENT; NITRIC ACID DERIVATIVE; OPIATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADULT; AGED; ANGINA PECTORIS; ANTIBODY TITER; ARTICLE; BLEEDING; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERANCE; DYSPNEA; ELECTIVE SURGERY; FEVER; HEART INFARCTION; HEMOPHILIA A; HEMOSTASIS; HUMAN; NORWAY; PRIORITY JOURNAL; PROTHROMBIN TIME; SURGICAL PATIENT; THORAX PAIN; VENOUS THROMBOEMBOLISM;

ADULT; AGED; BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE;

EID: 11044234837     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ehrenforth S, Kreutz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A. N Engl J Med 1990; 323: 1800-5.
3. Blatt PM, White GC, McMillan CW, Roberts HR. Treatment of antifactor VIII antibodies. Thromb Haemost 1977; 38: 514-23.
4. Blatt PM, Ménaché D, Roberts HR. A survey of the effectiveness of prothrombin complex concentrates in controlling haemorrhage in patients with haemophilia and anti.factor VIII antibodies. Thromb Haemost 1980; 44: 39-42.
5. Penner JA. Treatment of inhibitor patients with activated prothrombin complex concentrates. Prog Clin Biol Res 1984; 150 281-308.
6. Sjamsoedin LJM, Heijenen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
7. Bech RBM, Nielsen L, Falch JF et al. Evaluation of efficacy of recombinant factor VIIa in 149 patients treated for critical bleeds. Blood 1994; 84: 68 [Abstract].
8. Cohen I, Heim M, Martinowitz U, Chechick A. Orthopaedic outcome of total knee arthroplasty in haemophilic patients. Haemophilia 2000; 6: 104-9.
9. Negrier C, Goudemand J, Sultan Y et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
10. Hutchinson RJ, Penner JA, Hensinger RN. Anti-inhibitor coagulant complex (Autoplex) in hemophilia inhibitor patients undergoing synovectomy. Pediatrics 1983; 71: 631-3.
11. Yolken RH, Hilgartner MW. Prothrombin complex concentrates: use in treatment of hemophiliacs with factor VIII inhibitors. Am J Dis Child 1978; 132: 291-3.
12. Heisel MA, Gomerts ED, McComb JG, Hilgartner M. Use of activated prothrombin complex concentrates over multiple surgical episodes in a hemophilic child with inhibitor. J Pediatr 1983; 102: 951-4.
13. Hanna WT, Madigan RR, Miles MA, Lange RD. Activated factor IX complex in treatment of surgical cases of haemophilia A with inhibitors. Thromb Haemost 1981; 46: 638-41.
14. Mishra V, Tjønnfjord GE, Paus AC, Vaaler S. Orthopaedic surgery in severe bleeding disorders: a low volume, high cost procedure. Haemophilia 2002; 8: 809-14.
15. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28: 3-5.
16. Hough RE, Hampton KK, Preston FE et al. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex-related myocardial infarction in patients with haemophilia and inhibitors. Br J Haematol 2000; 111: 974-9.